AIA Group Ltd Has $6.98 Million Holdings in Johnson & Johnson (NYSE:JNJ)

AIA Group Ltd raised its stake in Johnson & Johnson (NYSE:JNJ) by 67.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,252 shares of the company’s stock after buying an additional 19,509 shares during the period. AIA Group Ltd’s holdings in Johnson & Johnson were worth $6,978,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in shares of Johnson & Johnson by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after buying an additional 431,205 shares in the last quarter. Partners in Financial Planning bought a new position in Johnson & Johnson during the fourth quarter worth $407,000. Everstar Asset Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $428,000. Delos Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 3.3% during the fourth quarter. Delos Wealth Advisors LLC now owns 2,530 shares of the company’s stock valued at $366,000 after purchasing an additional 80 shares during the period. Finally, Prevail Innovative Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $209,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $163.63 on Monday. The business’s 50-day moving average price is $158.68 and its 200-day moving average price is $156.07. The stock has a market cap of $394.32 billion, a P/E ratio of 24.61, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.29 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.